文献速递前列腺癌

根治性前列腺切除术后及挽救性放疗后照射野内前列腺癌复发

In-field prostate cancer recurrence following radical prostatectomy and salvage radiation.
PubMed 文献 · BJU Int · 2024-11-30

本研究基于单中心前瞻性前列腺癌登记数据库,2008至2021年间4575例患者中识别出108例(2.3%)根治性前列腺切除术后放疗后照射野内复发者,中位至复发时间78个月,比较冷冻消融、单独雄激素剥夺治疗与监测三种主要治疗方式的转移无生存、癌症特异性生存和总生存。

要点

  • 照射野内复发可在初始治疗后数年出现,中位至复发时间78个月。
  • 冷冻消融、单独ADT与监测三组间转移无生存(P=0.67)和总生存(P=0.07)无统计学显著差异。
  • ADT或冷冻消融组癌症特异性生存长于监测组(P=0.047)。

核心结论

  • 照射野内复发可在前列腺癌初始治疗完成后数年出现,局部和远处转移性复发常见且常需全身治疗。

研究设计与样本

  • 单中心前瞻性维护的前列腺癌登记数据库查询,2008至2021年根治性前列腺切除术后放疗后发生照射野内复发的108例患者。

主要发现

  • 4575例登记患者中108例(2.3%)识别为照射野内复发。
  • 从挽救治疗至照射野内复发的中位(四分位距)时间为78(50-126)个月。
  • 29例(26%)接受冷冻消融,23例(21%)接受ADT,28例(25%)接受监测。
  • 中位(四分位距)随访76(48-100)个月。
  • 三种主要治疗队列间转移无生存(P=0.67)或总生存(P=0.07)无统计学显著差异;ADT或冷冻消融组癌症特异性生存长于监测组(P=0.047)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To define the natural history, patterns of recurrence and treatment modalities for local prostate cancer (PCa) recurrence following radical prostatectomy (RP) and radiation therapy (RT), and to investigate factors that could predict metastasis-free survival (MFS) in this unique patient population. METHODS: We queried a prospectively maintained PCa registry to identify men developing in-field recurrence (IFR) following RP and RT from 2008 to 2021 at a single institution. IFR was defined as biopsy-proven recurrent PCa or the presence of persistent positron emission tomography-avid lesions in the prior radiation field without evidence of metastasis. Cox regression was conducted to determine predictors of MFS. Kaplan-Meier methods were used to calculate MFS, cancer-specific survival (CSS) and overall survival (OS) for patients in three primary therapy categories: cryoablation, androgen deprivation therapy (ADT) alone, and surveillance. RESULTS: Of 4575 patients from our registry, 108 (2.3%) with IFR were identified. The median (interquartile range [IQR]) time to IFR from salvage treatment was 78 (50-126) months. A total of 29 patients (26%) were managed with cryoablation, 23 (21%) with ADT, and 28 (25%) with surveillance. The median (IQR) follow-up was 76 (48-100) months. There were no statistically significant differences in MFS (P = 0.67) or OS (P = 0.07) among the three primary treatment cohorts. Patients treated with ADT or cryoablation had longer CSS compared to patients managed with surveillance (P = 0.047). CONCLUSIONS: We found that IFR may present years after completion of primary treatment for PCa. While curative management strategies may be attempted, local and distant metastatic recurrence is common and often requires systemic therapy.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Martin A, Mahmoud AM, Britton CJ, et al. In-field prostate cancer recurrence following radical prostatectomy and salvage radiation. BJU Int. 2024. PMID: 39614716. doi:10.1111/bju.16598

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。